Cargando…
Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics
In the recent of years, the use of lipid nanoparticles (LNPs) for RNA delivery has gained considerable attention, with a large number in the clinical pipeline as vaccine candidates or to treat a wide range of diseases. Microfluidics offers considerable advantages for their manufacture due to its sca...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697682/ https://www.ncbi.nlm.nih.gov/pubmed/33203082 http://dx.doi.org/10.3390/pharmaceutics12111095 |
_version_ | 1783615653857460224 |
---|---|
author | Roces, Carla B. Lou, Gustavo Jain, Nikita Abraham, Suraj Thomas, Anitha Halbert, Gavin W. Perrie, Yvonne |
author_facet | Roces, Carla B. Lou, Gustavo Jain, Nikita Abraham, Suraj Thomas, Anitha Halbert, Gavin W. Perrie, Yvonne |
author_sort | Roces, Carla B. |
collection | PubMed |
description | In the recent of years, the use of lipid nanoparticles (LNPs) for RNA delivery has gained considerable attention, with a large number in the clinical pipeline as vaccine candidates or to treat a wide range of diseases. Microfluidics offers considerable advantages for their manufacture due to its scalability, reproducibility and fast preparation. Thus, in this study, we have evaluated operating and formulation parameters to be considered when developing LNPs. Among them, the flow rate ratio (FRR) and the total flow rate (TFR) have been shown to significantly influence the physicochemical characteristics of the produced particles. In particular, increasing the TFR or increasing the FRR decreased the particle size. The amino lipid choice (cationic—DOTAP and DDAB; ionisable—MC3), buffer choice (citrate buffer pH 6 or TRIS pH 7.4) and type of nucleic acid payload (PolyA, ssDNA or mRNA) have also been shown to have an impact on the characteristics of these LNPs. LNPs were shown to have a high (>90%) loading in all cases and were below 100 nm with a low polydispersity index (≤0.25). The results within this paper could be used as a guide for the development and scalable manufacture of LNP systems using microfluidics. |
format | Online Article Text |
id | pubmed-7697682 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76976822020-11-29 Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics Roces, Carla B. Lou, Gustavo Jain, Nikita Abraham, Suraj Thomas, Anitha Halbert, Gavin W. Perrie, Yvonne Pharmaceutics Article In the recent of years, the use of lipid nanoparticles (LNPs) for RNA delivery has gained considerable attention, with a large number in the clinical pipeline as vaccine candidates or to treat a wide range of diseases. Microfluidics offers considerable advantages for their manufacture due to its scalability, reproducibility and fast preparation. Thus, in this study, we have evaluated operating and formulation parameters to be considered when developing LNPs. Among them, the flow rate ratio (FRR) and the total flow rate (TFR) have been shown to significantly influence the physicochemical characteristics of the produced particles. In particular, increasing the TFR or increasing the FRR decreased the particle size. The amino lipid choice (cationic—DOTAP and DDAB; ionisable—MC3), buffer choice (citrate buffer pH 6 or TRIS pH 7.4) and type of nucleic acid payload (PolyA, ssDNA or mRNA) have also been shown to have an impact on the characteristics of these LNPs. LNPs were shown to have a high (>90%) loading in all cases and were below 100 nm with a low polydispersity index (≤0.25). The results within this paper could be used as a guide for the development and scalable manufacture of LNP systems using microfluidics. MDPI 2020-11-15 /pmc/articles/PMC7697682/ /pubmed/33203082 http://dx.doi.org/10.3390/pharmaceutics12111095 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Roces, Carla B. Lou, Gustavo Jain, Nikita Abraham, Suraj Thomas, Anitha Halbert, Gavin W. Perrie, Yvonne Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics |
title | Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics |
title_full | Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics |
title_fullStr | Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics |
title_full_unstemmed | Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics |
title_short | Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics |
title_sort | manufacturing considerations for the development of lipid nanoparticles using microfluidics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697682/ https://www.ncbi.nlm.nih.gov/pubmed/33203082 http://dx.doi.org/10.3390/pharmaceutics12111095 |
work_keys_str_mv | AT rocescarlab manufacturingconsiderationsforthedevelopmentoflipidnanoparticlesusingmicrofluidics AT lougustavo manufacturingconsiderationsforthedevelopmentoflipidnanoparticlesusingmicrofluidics AT jainnikita manufacturingconsiderationsforthedevelopmentoflipidnanoparticlesusingmicrofluidics AT abrahamsuraj manufacturingconsiderationsforthedevelopmentoflipidnanoparticlesusingmicrofluidics AT thomasanitha manufacturingconsiderationsforthedevelopmentoflipidnanoparticlesusingmicrofluidics AT halbertgavinw manufacturingconsiderationsforthedevelopmentoflipidnanoparticlesusingmicrofluidics AT perrieyvonne manufacturingconsiderationsforthedevelopmentoflipidnanoparticlesusingmicrofluidics |